AstraZeneca: new clinical success for Lynparza

(CercleFinance.com) - On Wednesday AstraZeneca and its US partner Merck announced the success of a Phase III study for Lynparza in the treatment of advanced ovarian cancer, which has led to the share rising in morning trading on the London Stock Exchange.


Lynparza, a targeted cancer treatment, achieved its primary endpoint in the clinical trial by providing a statistically significant improvement in patient survival, without disease progression, compared to the current standard treatment.

AstraZeneca says that it now intends to contact international health authorities to inform them of these results.

Lynparza is already approved in about 60 countries for the treatment of certain types of ovarian cancer.

On Wednesday AstraZeneca shares are the second largest riser in the FTSE 100 index following these announcements, up about 1.3%.


Copyright (c) 2019 CercleFinance.com. All rights reserved.